Clinical Trials

The purpose of this study is to evaluate the safety and efficacy of Baricitinib (LY3009104) in cutaneous LP as assessed by the change in Physician Global Assessment (PGA) of skin, oral mucosa, and hair, Body Surface Area (BSA), Index Treatment and Control Lesion by Modified Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (mCAILS) score, Pruritus Visual Analog Scale (VAS), Verbal Rating Scale (VRS), Pruritus Numerical Rating Scale (NRS), and Skindex-16. To predict responses through the identification of unique biomarkers of LP at week 0 and utilizing RNA sequencing on responsive and non-responsive tissue at week 2. 

The purpose of this study is to evaluate the effects of topical INCB018424 PHOSPHATE CREAM 1.5% twice daily on lesions of cutaneous lichen planus (LP).

The primary purpose of the proof of concept study is to elucidate the efficacy of Secukinumab in the treatment of adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies, and to assess the safety and tolerability over 32 weeks.

The purpose of this study is to establish the effectiveness of ruxolitinib 1.5% cream BID (twice daily) in participants with cutaneous lichen planus (LP).

The primary objective of this study is to assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris. The primary measurement of efficacy will be with the Lichen Planopilaris Activity Index (LPPAI) before and after 6 months of treatment. Secondary measures of efficacy will be the mean follicular density, Physician Global assessment (PGA) score, and the Dermatology Quality of Life Index (DQLI) score before and after six months of therapy.

The purpose of this study is to assess the incidence and prevalence of oral squamous cell cancer in patients with oral lichen planus in Olmsted County 1986-2010.